Gastric Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 76 expanded access programs, clinical trials, and compassionate use pathways listed for Gastric Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with gastric cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 21 programs are currently active or recruiting, with the remaining 55 in other lifecycle stages. Sponsors actively running programs in this area include AstraZeneca, National Cancer Institute (NCI), Amgen, Daiichi Sankyo, Merus N.V., and others.
By recruiting status
Snapshot of where every Gastric Cancer program currently sits in its lifecycle.
- Active / Recruiting21
- Inactive55
Top sponsors
Organisations running the most Gastric Cancer programs in the directory.
- AstraZeneca10 programs
- National Cancer Institute (NCI)3 programs
- Amgen2 programs
- Daiichi Sankyo2 programs
- Merus N.V.2 programs
- 858 Therapeutics, Inc.1 program
- ALX Oncology Inc.1 program
- Anwaar Saeed1 program
- Apollomics Inc.1 program
- Artiva Biotherapeutics, Inc.1 program
Gastric Cancer programs (76)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on [18F]FPyQCP PET Imaging for Detecting Certain Types of Cancer — Blue Earth Diagnostics
- Study on Using [18F]FAPI-74 PET Imaging for Detecting Cancer — National Cancer Institute (NCI)
- Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
- Phase 3 Study of HLX22 with Trastuzumab and Chemotherapy for Treating Gastroesophageal Junction and Gastric Cancer — Shanghai Henlius Biotech
- Study on Cadonilimab and Chemotherapy for Gastric or Gastroesophageal Junction Cancer — Memorial Sloan Kettering Cancer Center
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Study on PARG Inhibitor ETX-19477 for Patients with Advanced Solid Cancers — 858 Therapeutics, Inc.
- Study on Cabozantinib and Durvalumab, With or Without Tremelimumab, for Patients with Gastroesophageal and Other Gastrointestinal Cancers — Anwaar Saeed
- Study on Claudin18.2 CAR-T Therapy for Patients with Advanced Gastric, Pancreatic, or Other Digestive Cancers — CARsgen Therapeutics Co., Ltd.
- Study on FOG-001 for Advanced or Metastatic Solid Tumors — Fog Pharmaceuticals, Inc.
- Study on Givastomig with Nivolumab and Chemotherapy for Adults with CLDN18.2 Positive Metastatic Stomach Cancer — I-Mab Biopharma US Limited
- Screening and Treatment for Helicobacter Pylori in At-risk Communities in South Florida — University of Miami
- Study on Using CYTALUX™ for Imaging Gastrointestinal Cancers During Surgery — Cedars-Sinai Medical Center
- Study on Lead-212 PSV359 Therapy for Patients with Solid Tumors — Perspective Therapeutics
- Study on BHB810 for Advanced Stomach and Gastroesophageal Cancer — BigHat Biosciences, Inc.
- Study on Ramucirumab and Paclitaxel for Gastric or Gastroesophageal Junction Cancer in France — Eli Lilly and Company
- Study on Sonesitatug Vedotin and Capecitabine, With or Without Rilvegostomig, for Advanced Stomach and Esophageal Cancer — AstraZeneca
- Study on AZD4360 for Adults with Advanced Solid Tumors — AstraZeneca
- Study on Anti-CEACAM5 ADC M9140 for Advanced Solid Tumors (PROCEADE PanTumor) — EMD Serono Research & Development Institute, Inc.
- Study on Dato-Dxd Alone and with Other Cancer Treatments for Advanced Solid Tumors (TROPION-PanTumor03) — AstraZeneca
- Study on TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab for First-Line Treatment of Advanced HER2-Positive Gastric or Gastroesophageal Junction Cancer — Daiichi Sankyo
- Study on BLU-222 for Advanced Solid Tumors — Blueprint Medicines Corporation
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Study on the Safety and Effectiveness of AB-201 for Advanced HER2+ Solid Tumors — Artiva Biotherapeutics, Inc.
- Study on CHM-2101 CAR T Cell Therapy for Advanced Gastrointestinal Cancers — Chimeric Therapeutics
- Phase II Study of Laparoscopic Heated Chemotherapy and Chemoradiation Before Surgery for Stomach Cancer — Icahn School of Medicine at Mount Sinai
- Study on the Safety and Effectiveness of NC410 and Pembrolizumab for Advanced Solid Tumors — NextCure, Inc.
- Study on Bemarituzumab with Other Cancer Treatments for Advanced Stomach or Gastroesophageal Junction Cancer — Amgen
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — Merus N.V.
- Study on Evorpacept (ALX148) for Patients with Advanced HER2+ Gastric Cancer — ALX Oncology Inc.
- Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study on Navicixizumab Alone or Combined with Other Treatments for Advanced Solid Tumors — OncXerna Theraputics, Inc.
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on TAK-500 With or Without Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors — Takeda
- Study on TRK-950 with Ramucirumab and Paclitaxel for Treating Gastric Cancer — Toray Industries, Inc
- Study on Zolbetuximab for Adults with Stomach and Gastroesophageal Cancer — Astellas Pharma Global Development, Inc.
- Study on the Safety and Effectiveness of AZD7789 in Adults with Advanced or Metastatic Solid Cancer — AstraZeneca
- Study on the Safety and Tolerability of TST001 for Advanced or Metastatic Solid Tumors — Suzhou Transcenta Therapeutics Co., Ltd.
- Using Modified White Blood Cells to Target G12D Mutated RAS in Cancer Patients with HLA-A*11:01 — National Cancer Institute (NCI)
- Study on Using Genetically Modified White Blood Cells to Treat Cancers with a Specific KRAS Mutation in HLA-A*11:01 Patients — National Cancer Institute (NCI)
- Study on Using Tumor Infiltrating Lymphocytes for Treating Advanced Solid Cancers — Udai Kammula
- Study on APL-101 for Treating Advanced Solid Tumors with Specific Genetic Changes — Apollomics Inc.
- Study on Avutometinib and Defactinib for Diffuse Stomach Cancer — Ryan H. Moy, MD, PhD
- Study Comparing AZD0901 with Other Treatments for Advanced Stomach or Gastroesophageal Cancer with Claudin18.2 Expression — AstraZeneca
- Study on AZD0901 for Patients with Advanced Solid Tumors Expressing Claudin18.2 — AstraZeneca
- Study on Bemarituzumab with Chemotherapy and Nivolumab Compared to Chemotherapy and Nivolumab for Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2b Overexpression — Amgen
- Study on Combining TATE and PD-1 Inhibitor for Liver Cancer — Teclison Ltd.
- Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Expanded Access Use of DKN-01 for Treating Advanced Solid Tumors — Leap Therapeutics, Inc.
- Study on the Feasibility of Using the LUM Imaging System to Detect Gastrointestinal Cancers — Lumicell, Inc.
- Study on Neratinib with Chemotherapy, Trastuzumab, and Pembrolizumab for HER2 Gastroesophageal Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma — AstraZeneca
- Study on New Immunotherapy with Anti-Angiogenesis and Chemotherapy for Advanced Gastroesophageal Cancer — Harry H Yoon
- Study on Oral Q702 and Pembrolizumab for Advanced Esophageal, Gastric, Liver, and Cervical Cancers — Qurient Co., Ltd.
- Study on the Safety and Effectiveness of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) — AstraZeneca
- Study on MCLA-129 Antibody Treatment for Advanced Lung and Other Solid Tumors — Merus N.V.
- Phase I Study of Sorafenib with FOLFOX4 as First-Line Treatment for Advanced or Metastatic Stomach Cancer — Chinese Academy of Medical Sciences
- Phase II Study on the Effects of Heated Chemotherapy During Laparoscopic Surgery for Advanced Stomach Cancer — University of Chicago
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on RAPA-201 Therapy for Solid Tumors — Rapa Therapeutics LLC
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study of AZD5305 Alone and with Other Cancer Treatments in Patients with Advanced Solid Tumors — AstraZeneca
- Study on AZD5863 for Adults with Advanced or Metastatic Solid Tumors — AstraZeneca
- Study on CBX-12 for Patients with Advanced or Metastatic Solid Tumors — Cybrexa Therapeutics
- Study on INBRX-106 Alone and with Pembrolizumab (Keytruda®) for Advanced Solid Tumors — Inhibrx Biosciences, Inc
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study on SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers — University of Colorado, Denver
- Study on Sequential Systemic Therapy and Intraperitoneal Paclitaxel for Stomach and Gastroesophageal Cancer with Peritoneal Spread — University of California, Irvine
- Study on the Safety and Effectiveness of IDX-1197 with XELOX or Irinotecan for Advanced Stomach Cancer — Idience Co., Ltd.
- Study on the Effectiveness of PIPAC and Minimally Invasive Surgery in High-Risk Stomach Cancer Patients — Odense University Hospital
- Study on Short Course Radiation Therapy Combined with Chemotherapy for Early Stage Gastric Cancer — Washington University School of Medicine
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Gastric Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.